Research article
Clinical practice guidelines for the care and treatment of breast cancer: 13. Sentinel lymph node biopsy
Jacques Cantin, Hugh Scarth, Mark Levine, Maria Hugi and The Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer
CMAJ July 24, 2001 165 (2) 166-173;
Jacques Cantin
Dr. Cantin is Associate Professor at the University of Montreal and is with the Centre hospitalier de l'Université de Montréal, Montreal, Que.; Dr. Scarth is Assistant Professor, Department of Surgery, Dalhousie University, and is with the Atlantic Health Sciences Corporation, Saint John, NB; Dr. Levine is Professor in the Departments of Medicine and Clinical Epidemiology and Biostatistics, McMaster University, and is the Buffet Taylor Chair in Breast Cancer Research, McMaster University, Hamilton, Ont.; and Dr. Hugi is with Providence Health Care, Vancouver, BC. Dr. Mark Levine (Cancer Care Ontario), Hamilton Regional Cancer Centre and McMaster University, Hamilton, Ont. Dr. David M. Bowman (Manitoba Cancer Treatment and Research Foundation), Manitoba Cancer Treatment and Research Foundation, Winnipeg, Man.; Dr. Judy Caines (Federal/Provincial/Territorial Advisory Committee on Health Services), Nova Scotia Cancer Centre, Halifax, NS; Dr. Jacques Cantin (Royal College of Physicians and Surgeons of Canada), Centre hospitalier de l'Université de Montréal, Montreal, Que.; Ms. Chris Emery (Canadian Nurses Association), BC Cancer Agency, Delta, BC; Dr. Eva Grunfeld (College of Family Physicians of Canada), Ottawa Regional Cancer Centre, Ottawa, Ont.; Dr. Maria R. Hugi (Canadian Breast Cancer Network), Providence Health Care, Vancouver, BC; Dr. Alan W. Lees (Alberta Cancer Board), Cross Cancer Institute, Edmongon, Alta.; Ms. Sabina Mallard (Canadian Breast Cancer Network), consumer representative, Stratford, PEI; Dr. Mohamed Mohamed (Saskatchewan Cancer Foundation), Saskatoon Cancer Centre, Saskatoon, Sask.; Dr. Ivo A. Olivotto (BC Cancer Agency), Vancouver Island Cancer Centre and University of British Columbia, Victoria, BC; Dr. Leonard Reyno (Cancer Care Nova Scotia), Nova Scotia Cancer Centre, Halifax, NS; Dr. Carol Sawka (Cancer Care Ontario), Toronto Sunnybrook Regional Cancer Centre, Toronto, Ont.; Dr. Hugh Scarth (Atlantic Health Sciences Corporation), Saint John Regional Hospital, Saint John, NB; Ms. Donna Seymour (Health Canada), Adult Health Division, Centre for Chronic Disease and Control, Health Canada, Ottawa, Ont.; Dr. S. Kishore Thain (Newfoundland Cancer Treatment and Research Foundation), Dr. H.B. Murphy Cancer Centre, St. John's, Nfld.; Dr. Timothy Whelan (Cancer Care Ontario), Hamilton Regional Cancer Centre and McMaster University, Hamilton, Ont.; and, at the time of writing, Dr. Jean Deschênes (Comité consultatif sur le cancer du Québec), Jewish General Hospital, Quebec, Que.; Dr. L. Arthur Firth (Saskatchewan Cancer Foundation), Allan Blair Cancer Centre, Regina, Sask.; Dr. Maureen C. Nolan (Cancer Treatment and Research Foundation of Nova Scotia), Nova Scotia Cancer Centre, Halifax, NS; and Dr. John W. Sellors (College of Family Physicians of Canada), McMaster University, Hamilton, Ont.
Hugh Scarth
Dr. Cantin is Associate Professor at the University of Montreal and is with the Centre hospitalier de l'Université de Montréal, Montreal, Que.; Dr. Scarth is Assistant Professor, Department of Surgery, Dalhousie University, and is with the Atlantic Health Sciences Corporation, Saint John, NB; Dr. Levine is Professor in the Departments of Medicine and Clinical Epidemiology and Biostatistics, McMaster University, and is the Buffet Taylor Chair in Breast Cancer Research, McMaster University, Hamilton, Ont.; and Dr. Hugi is with Providence Health Care, Vancouver, BC. Dr. Mark Levine (Cancer Care Ontario), Hamilton Regional Cancer Centre and McMaster University, Hamilton, Ont. Dr. David M. Bowman (Manitoba Cancer Treatment and Research Foundation), Manitoba Cancer Treatment and Research Foundation, Winnipeg, Man.; Dr. Judy Caines (Federal/Provincial/Territorial Advisory Committee on Health Services), Nova Scotia Cancer Centre, Halifax, NS; Dr. Jacques Cantin (Royal College of Physicians and Surgeons of Canada), Centre hospitalier de l'Université de Montréal, Montreal, Que.; Ms. Chris Emery (Canadian Nurses Association), BC Cancer Agency, Delta, BC; Dr. Eva Grunfeld (College of Family Physicians of Canada), Ottawa Regional Cancer Centre, Ottawa, Ont.; Dr. Maria R. Hugi (Canadian Breast Cancer Network), Providence Health Care, Vancouver, BC; Dr. Alan W. Lees (Alberta Cancer Board), Cross Cancer Institute, Edmongon, Alta.; Ms. Sabina Mallard (Canadian Breast Cancer Network), consumer representative, Stratford, PEI; Dr. Mohamed Mohamed (Saskatchewan Cancer Foundation), Saskatoon Cancer Centre, Saskatoon, Sask.; Dr. Ivo A. Olivotto (BC Cancer Agency), Vancouver Island Cancer Centre and University of British Columbia, Victoria, BC; Dr. Leonard Reyno (Cancer Care Nova Scotia), Nova Scotia Cancer Centre, Halifax, NS; Dr. Carol Sawka (Cancer Care Ontario), Toronto Sunnybrook Regional Cancer Centre, Toronto, Ont.; Dr. Hugh Scarth (Atlantic Health Sciences Corporation), Saint John Regional Hospital, Saint John, NB; Ms. Donna Seymour (Health Canada), Adult Health Division, Centre for Chronic Disease and Control, Health Canada, Ottawa, Ont.; Dr. S. Kishore Thain (Newfoundland Cancer Treatment and Research Foundation), Dr. H.B. Murphy Cancer Centre, St. John's, Nfld.; Dr. Timothy Whelan (Cancer Care Ontario), Hamilton Regional Cancer Centre and McMaster University, Hamilton, Ont.; and, at the time of writing, Dr. Jean Deschênes (Comité consultatif sur le cancer du Québec), Jewish General Hospital, Quebec, Que.; Dr. L. Arthur Firth (Saskatchewan Cancer Foundation), Allan Blair Cancer Centre, Regina, Sask.; Dr. Maureen C. Nolan (Cancer Treatment and Research Foundation of Nova Scotia), Nova Scotia Cancer Centre, Halifax, NS; and Dr. John W. Sellors (College of Family Physicians of Canada), McMaster University, Hamilton, Ont.
Mark Levine
Dr. Cantin is Associate Professor at the University of Montreal and is with the Centre hospitalier de l'Université de Montréal, Montreal, Que.; Dr. Scarth is Assistant Professor, Department of Surgery, Dalhousie University, and is with the Atlantic Health Sciences Corporation, Saint John, NB; Dr. Levine is Professor in the Departments of Medicine and Clinical Epidemiology and Biostatistics, McMaster University, and is the Buffet Taylor Chair in Breast Cancer Research, McMaster University, Hamilton, Ont.; and Dr. Hugi is with Providence Health Care, Vancouver, BC. Dr. Mark Levine (Cancer Care Ontario), Hamilton Regional Cancer Centre and McMaster University, Hamilton, Ont. Dr. David M. Bowman (Manitoba Cancer Treatment and Research Foundation), Manitoba Cancer Treatment and Research Foundation, Winnipeg, Man.; Dr. Judy Caines (Federal/Provincial/Territorial Advisory Committee on Health Services), Nova Scotia Cancer Centre, Halifax, NS; Dr. Jacques Cantin (Royal College of Physicians and Surgeons of Canada), Centre hospitalier de l'Université de Montréal, Montreal, Que.; Ms. Chris Emery (Canadian Nurses Association), BC Cancer Agency, Delta, BC; Dr. Eva Grunfeld (College of Family Physicians of Canada), Ottawa Regional Cancer Centre, Ottawa, Ont.; Dr. Maria R. Hugi (Canadian Breast Cancer Network), Providence Health Care, Vancouver, BC; Dr. Alan W. Lees (Alberta Cancer Board), Cross Cancer Institute, Edmongon, Alta.; Ms. Sabina Mallard (Canadian Breast Cancer Network), consumer representative, Stratford, PEI; Dr. Mohamed Mohamed (Saskatchewan Cancer Foundation), Saskatoon Cancer Centre, Saskatoon, Sask.; Dr. Ivo A. Olivotto (BC Cancer Agency), Vancouver Island Cancer Centre and University of British Columbia, Victoria, BC; Dr. Leonard Reyno (Cancer Care Nova Scotia), Nova Scotia Cancer Centre, Halifax, NS; Dr. Carol Sawka (Cancer Care Ontario), Toronto Sunnybrook Regional Cancer Centre, Toronto, Ont.; Dr. Hugh Scarth (Atlantic Health Sciences Corporation), Saint John Regional Hospital, Saint John, NB; Ms. Donna Seymour (Health Canada), Adult Health Division, Centre for Chronic Disease and Control, Health Canada, Ottawa, Ont.; Dr. S. Kishore Thain (Newfoundland Cancer Treatment and Research Foundation), Dr. H.B. Murphy Cancer Centre, St. John's, Nfld.; Dr. Timothy Whelan (Cancer Care Ontario), Hamilton Regional Cancer Centre and McMaster University, Hamilton, Ont.; and, at the time of writing, Dr. Jean Deschênes (Comité consultatif sur le cancer du Québec), Jewish General Hospital, Quebec, Que.; Dr. L. Arthur Firth (Saskatchewan Cancer Foundation), Allan Blair Cancer Centre, Regina, Sask.; Dr. Maureen C. Nolan (Cancer Treatment and Research Foundation of Nova Scotia), Nova Scotia Cancer Centre, Halifax, NS; and Dr. John W. Sellors (College of Family Physicians of Canada), McMaster University, Hamilton, Ont.
Maria Hugi
Dr. Cantin is Associate Professor at the University of Montreal and is with the Centre hospitalier de l'Université de Montréal, Montreal, Que.; Dr. Scarth is Assistant Professor, Department of Surgery, Dalhousie University, and is with the Atlantic Health Sciences Corporation, Saint John, NB; Dr. Levine is Professor in the Departments of Medicine and Clinical Epidemiology and Biostatistics, McMaster University, and is the Buffet Taylor Chair in Breast Cancer Research, McMaster University, Hamilton, Ont.; and Dr. Hugi is with Providence Health Care, Vancouver, BC. Dr. Mark Levine (Cancer Care Ontario), Hamilton Regional Cancer Centre and McMaster University, Hamilton, Ont. Dr. David M. Bowman (Manitoba Cancer Treatment and Research Foundation), Manitoba Cancer Treatment and Research Foundation, Winnipeg, Man.; Dr. Judy Caines (Federal/Provincial/Territorial Advisory Committee on Health Services), Nova Scotia Cancer Centre, Halifax, NS; Dr. Jacques Cantin (Royal College of Physicians and Surgeons of Canada), Centre hospitalier de l'Université de Montréal, Montreal, Que.; Ms. Chris Emery (Canadian Nurses Association), BC Cancer Agency, Delta, BC; Dr. Eva Grunfeld (College of Family Physicians of Canada), Ottawa Regional Cancer Centre, Ottawa, Ont.; Dr. Maria R. Hugi (Canadian Breast Cancer Network), Providence Health Care, Vancouver, BC; Dr. Alan W. Lees (Alberta Cancer Board), Cross Cancer Institute, Edmongon, Alta.; Ms. Sabina Mallard (Canadian Breast Cancer Network), consumer representative, Stratford, PEI; Dr. Mohamed Mohamed (Saskatchewan Cancer Foundation), Saskatoon Cancer Centre, Saskatoon, Sask.; Dr. Ivo A. Olivotto (BC Cancer Agency), Vancouver Island Cancer Centre and University of British Columbia, Victoria, BC; Dr. Leonard Reyno (Cancer Care Nova Scotia), Nova Scotia Cancer Centre, Halifax, NS; Dr. Carol Sawka (Cancer Care Ontario), Toronto Sunnybrook Regional Cancer Centre, Toronto, Ont.; Dr. Hugh Scarth (Atlantic Health Sciences Corporation), Saint John Regional Hospital, Saint John, NB; Ms. Donna Seymour (Health Canada), Adult Health Division, Centre for Chronic Disease and Control, Health Canada, Ottawa, Ont.; Dr. S. Kishore Thain (Newfoundland Cancer Treatment and Research Foundation), Dr. H.B. Murphy Cancer Centre, St. John's, Nfld.; Dr. Timothy Whelan (Cancer Care Ontario), Hamilton Regional Cancer Centre and McMaster University, Hamilton, Ont.; and, at the time of writing, Dr. Jean Deschênes (Comité consultatif sur le cancer du Québec), Jewish General Hospital, Quebec, Que.; Dr. L. Arthur Firth (Saskatchewan Cancer Foundation), Allan Blair Cancer Centre, Regina, Sask.; Dr. Maureen C. Nolan (Cancer Treatment and Research Foundation of Nova Scotia), Nova Scotia Cancer Centre, Halifax, NS; and Dr. John W. Sellors (College of Family Physicians of Canada), McMaster University, Hamilton, Ont.
Dr. Cantin is Associate Professor at the University of Montreal and is with the Centre hospitalier de l'Université de Montréal, Montreal, Que.; Dr. Scarth is Assistant Professor, Department of Surgery, Dalhousie University, and is with the Atlantic Health Sciences Corporation, Saint John, NB; Dr. Levine is Professor in the Departments of Medicine and Clinical Epidemiology and Biostatistics, McMaster University, and is the Buffet Taylor Chair in Breast Cancer Research, McMaster University, Hamilton, Ont.; and Dr. Hugi is with Providence Health Care, Vancouver, BC. Dr. Mark Levine (Cancer Care Ontario), Hamilton Regional Cancer Centre and McMaster University, Hamilton, Ont. Dr. David M. Bowman (Manitoba Cancer Treatment and Research Foundation), Manitoba Cancer Treatment and Research Foundation, Winnipeg, Man.; Dr. Judy Caines (Federal/Provincial/Territorial Advisory Committee on Health Services), Nova Scotia Cancer Centre, Halifax, NS; Dr. Jacques Cantin (Royal College of Physicians and Surgeons of Canada), Centre hospitalier de l'Université de Montréal, Montreal, Que.; Ms. Chris Emery (Canadian Nurses Association), BC Cancer Agency, Delta, BC; Dr. Eva Grunfeld (College of Family Physicians of Canada), Ottawa Regional Cancer Centre, Ottawa, Ont.; Dr. Maria R. Hugi (Canadian Breast Cancer Network), Providence Health Care, Vancouver, BC; Dr. Alan W. Lees (Alberta Cancer Board), Cross Cancer Institute, Edmongon, Alta.; Ms. Sabina Mallard (Canadian Breast Cancer Network), consumer representative, Stratford, PEI; Dr. Mohamed Mohamed (Saskatchewan Cancer Foundation), Saskatoon Cancer Centre, Saskatoon, Sask.; Dr. Ivo A. Olivotto (BC Cancer Agency), Vancouver Island Cancer Centre and University of British Columbia, Victoria, BC; Dr. Leonard Reyno (Cancer Care Nova Scotia), Nova Scotia Cancer Centre, Halifax, NS; Dr. Carol Sawka (Cancer Care Ontario), Toronto Sunnybrook Regional Cancer Centre, Toronto, Ont.; Dr. Hugh Scarth (Atlantic Health Sciences Corporation), Saint John Regional Hospital, Saint John, NB; Ms. Donna Seymour (Health Canada), Adult Health Division, Centre for Chronic Disease and Control, Health Canada, Ottawa, Ont.; Dr. S. Kishore Thain (Newfoundland Cancer Treatment and Research Foundation), Dr. H.B. Murphy Cancer Centre, St. John's, Nfld.; Dr. Timothy Whelan (Cancer Care Ontario), Hamilton Regional Cancer Centre and McMaster University, Hamilton, Ont.; and, at the time of writing, Dr. Jean Deschênes (Comité consultatif sur le cancer du Québec), Jewish General Hospital, Quebec, Que.; Dr. L. Arthur Firth (Saskatchewan Cancer Foundation), Allan Blair Cancer Centre, Regina, Sask.; Dr. Maureen C. Nolan (Cancer Treatment and Research Foundation of Nova Scotia), Nova Scotia Cancer Centre, Halifax, NS; and Dr. John W. Sellors (College of Family Physicians of Canada), McMaster University, Hamilton, Ont.
Table1
References
- 1.↵
Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. Clinical practice guidelines for the care and treatment of breast cancer. CMAJ 1998;158(3 Suppl). Available: www.cma.ca/cmaj/vol-158/issue-3/breastcpg/index.htm
- 2.↵
- 3.↵
- 4.↵
- 5.↵
Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. Clinical practice guidelines for the care and treatment of breast cancer: 4. Axillary dissection. CMAJ 1998;158(3 Suppl):S22-6. Available: www.cma.ca/cmaj/vol-158/issue-3/breastcpg/index.htm
- 6.↵
Overgaard M, Hansen PS, Overgaard J, Rose C, Andersson M, Bach F, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med 1997;337:949-55.
- 7.↵
Ragaz J, Jackson SM, Le N, Plenderleith IH, Spinelli JJ, Basco VE, et al. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med 1997;337:956-62.
- 8.↵
Overgaard M, Jensen MB, Overgaard J, Hansen PS, Rose C, Andersson M, et al. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet 1999;353:1641-8.
- 9.↵
Harris SR, Hugi MR, Olivotto IA, Levine M, for the Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. Clinical practice guidelines for the care and treatment of breast cancer: 11. Lymphedema. CMAJ 2001;164:191-9. Available: www.cma.ca/cmaj/vol-164/issue-2/0191.htm
- 10.↵
Schrenk P, Rieger R, Shaniyeh A, Wayand W. Morbidity following lymph node biopsy versus axillary lymph node dissection for patients with breast carcinoma. Cancer 2000;88:608-14.
- 11.↵
Carter CL, Allen C, Henson DE. Relation of tumour size, lymph node status and survival in 24740 breast cancer cases. Cancer 1989;63:181-7.
- 12.↵
Giuliano AE, Jones RC, Brennan M, Statman R. Sentinel lymphadenectomy in breast cancer. J Clin Oncol 1997;15:2345-60.
- 13.↵
In: Roses DF, editor. Breast cancer. Philadelphia: Churchill Livingstone; 1999. p. 253-8.
- 14.↵
Morrow M, Rademaker AW, Bethke KP, Talamonti MS, Dawes LG, Clauson J, et al. Learning sentinel biopsy: results of a prospective randomized trial of two techniques. Surgery 1999;126:714-22.
- 15.↵
Cox CE, Bass S, McCann C, Wang J, Bolano M, Durand K, et al. Learning curves for sentinel lymph node mapping breast cancer base on surgical volume analysis. Society of Surgical Oncology meeting; 2000 Mar 16–19; New Orleans.
- 16.↵
Crossin JA, Johnson C, Stewart PB, Turner WW. Gamma-probe-guided resection of the sentinel lymph node in breast cancer. Am Surg 1998;7:666-9.
- 17.↵
Krag DN, Weaver DL, Ashikaga T, Moffat F, Klimberg VS, Shriver C, et al. The sentinel node in breast cancer: a multicenter validation study.N Engl J Med 1998;339:941-6.
- 18.↵
Barnwell JM, Arrendondo MA, Kollmorgen D, Gibbs JF, Lamonica D, Carson W, et al. Sentinel node biopsy in breast cancer. Ann Surg Oncol 1998;5: 126-30.
- 19.↵
Offodile R, Hoh C, Barsky SH, Nelson SD, Elashoff R, Eilber FR, et al. Minimally invasive breast cancer staging using lymphatic mapping with radiolabeled dextran. Cancer 1998;82:1704-8.
- 20.↵
- 21.↵
De Cicco C, Cremonesi M, Luini A, Bartolomei M, Grana C, Prisco G, et al. Lymphoscintigraphy and radioguided biopsy of the sentinel axillary node in breast cancer.J Nucl Med 1998;39:2080-4.
- 22.↵
- 23.↵
Snider H, Dowlatshahi K, Fan M, Bridger WM, Rayudu G, Oleske D. Sentinel node biopsy in the staging of breast cancer.Am J Surg 1998;176:305-10.
- 24.↵
Gulec SA, Moffat FL, Carrol RG, Serafini AN, Sfakianakis GN, Allen L, et al. Sentinel lymph node localization in early breast cancer.J Nucl Med 1998;8: 1388-93.
- 25.↵
- 26.↵
Imoto S, Hasebe T. Initial experience with sentinel node biopsy in breast cancer at the National Cancer Center Hospital East. Jpn J Clin Oncol 1999;29:11-5.
- 27.↵
Miner TJ, Shriver CD, Jaques DP, Maniscalco-Theberge ME, Krag DN. Ultrasonographically guided injection improves localization of the radiolabeled sentinel lymph node in breast cancer. Ann Surg Oncol 1998;5:315-21.
- 28.↵
Sandrucci S, Mussa A. Sentinel lymph node biopsy and axillary staging of T1-T2 N0 breast cancer: a multicenter study. Semin Surg Oncol 1998;15:278-83.
- 29.↵
Paganelli G, De Cicco C, Cremonesi M, Prisco G, Calza P, Luini A, et al. Optimized sentinel node scintigraphy in breast cancer.Q J Nucl Med 1998;42: 49-53.
- 30.↵
- 31.↵
Cox CE, Pendas S, Cox JM, Joseph E, Shons AR, Yeatman T, et al. Guidelines for sentinel node biopsy and lymphatic mapping of patients with breast cancer. Ann Surg 1998;227:645-53.
- 32.↵
O'Hea BJ, Hill ADK, El-Shirbiny A, Yeh SD, Rosen PP, Coit DG, et al. Sentinel lymph node biopsy in breast cancer: initial experience at Memorial Sloan–Kettering Cancer Center. J Am Coll Surg 1998;186:423-7.
- 33.↵
Pijpers R, Meijer S, Hoekstra OS, Collet GJ, Comans EF, Boom RP, et al. Impact of lymphoscintigraphy on sentinel node identification with technetium-9m-colloidal albumin in breast cancer. J Nucl Med 1997;38:366-8.
- 34.↵
- 35.↵
Turner RR, Ollila DW, Krasne DL, Giuliano AE. Histopathalogic validation of the sentinel lymph node hypothesis for breast carcinoma. Ann Surg 1997; 226: 271-8.
- 36.↵
Flett MM, Going JJ, Stanton PD, Cooke TG. Sentinel node localization in patients with breast cancer. Br J Surg 1998; 85:991-3.
- 37.↵
Guenther JM, Krishnamoorthy M, Tan LR. Sentinel lymphadenctomy for breast cancer in a community managed care setting. Cancer J Sci Am 1997;3: 336-40.
- 38.↵
Veronesi U, Paganelli G, Galimberti V, Viale G, Zurrida S, Bedoni M, et al. Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes. Lancet 1997;349:1864-7.
- 39.↵
Borgstein PJ, Pijpers R, Comans EF, van Diest PJ, Boom RP, Meijer S, et al. Sentinel lymph node biopsy in breast cancer: guidelines and pitfalls of lymphoscintigraphy and gamma probe detection. J Am Coll Surg 1998;186:275-83.
- 40.↵
- 41.↵
Albertini JJ, Lyman GH, Cox C, Yeatman T, Balducci L, Ku N, et al. Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. JAMA 1996;276:1818-22.
- 42.↵
Rodier JF, Janser JC, Barlier-Pagel C, Ghnassia J, Velten M. Sentinel axillary lymphadenectomy with intraoperative lymphatic mapping in breast cancer. Adv Ther 1996;13:347-54.
- 43.↵
Giuliano AE, Barth M, Spivack B, Beitsch PD, Evans SW. Incidence and predictors of axillary metastastasis in T1 carcinoma of the breast. J Am Coll Surg 1996; 183: 185-9.
- 44.↵
Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenctomy for breast cancer. Ann Surg 1994;220:391-8.
- 45.↵
Ratanawichitrasin A, Biscotti CV, Levy L, Crowe JP. Touch imprint cytological analysis of sentinel lymph nodes for detecting axillary metastases in patients with breast cancer. Br J Surg 1999;86:1346-9.
- 46.↵
Cserni G, Boross G, Baltas B. Value of axillary sentinel nodal status in breast cancer. World J Surg 2000;24:341-4.
- 47.↵
Haigh PI, Hansen NM, Qi K, Guilano AE. Biopsy method and excision volume do not affect success rate of subsequent sentinel lymph node dissection in breast cancer. Ann Surg Oncol 2000;7:21-7.
- 48.↵
Molland JG, Dias MM, Gillett DJ. Sentinel node biopsy in breast cancer: results of 103 cases. Aust N Z J Surg 2000;70:98-102.
- 49.↵
Kollias J, Gill PG, Chatterton BE, Hall VE, Bochner MA, Coventry BJ, et al. Reliability of sentinel node status in predicting axillary lymph node involvement in breast cancer. Med J Aust 1999;171:461-5.
- 50.↵
Czerniecki BJ, Scheff AM, Callans LS, Spitz FR, Bedrosian I, Conant EF, et al. Immunohistochemistry with Pancytokeratins improves the sensitivity of sentinel lymph node biopsy in patients with breast carcinoma.Cancer 1999;85: 1098-103.
- 51.↵
Kern KA. Sentinel lymph node mapping in breast cancer using subareolar injection of blue dye. J Am Coll Surg 1999;189:539-45.
- 52.↵
Krag DN, Weaver DL, Alex JC, Fairbank JT. Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe. Surg Oncol 1993;2:335-40.
- 53.↵
Bass SS, Cox CE, Ku NN, Berman C, Reintgen DS. The role of sentinel lymph node biopsy in breast cancer. J Am Coll Surg 1999;189:183-94.
- 54.↵
Weaver Dl, Krag DN, Takamura A, Seth PH, O'Connell M. Pathologic analysis of sentinel and nonsentinel lymph nodes in breast carcinoma. Cancer 2000; 88: 1099-107.
- 55.↵
- 56.↵
Roumen RMH, Valkenburg JGM, Geuskens LM. Lymphoscintigraphy and feasibility of sentinel node biopsy in 83 patients with primary breast cancer. Eur J Surg Oncol 1997;23:495-502.
- 57.↵
Hill ADK, Tran KN, Akhurst T, Yeung H, Yeh SDJ, Rosen PP, et al. Lessons learned from 500 cases of lymphatic mapping for breast cancer. Ann Surg 1999;229:528-35.
- 58.↵
- 59.↵
McMasters KM, Tuttle TM, Carlson DJ, Brown CM, Noyes RD, Glaser RL, et al. Sentinel lymph node biopsy for breast cancer: a suitable alternative to routine axillary dissection in multi-institutional practice when optimal technique is used. J Clin Oncol 2000;18:2560-6.
- 60.↵
Morgan A, Howisey RL, Aldape HC, Patton RG, Rowbotham RK, Schmidt EK, et al. Initial experience in a community hospital with sentinel lymph node mapping and biopsy for evaluation of axillary lymph node status in palpable invasive breast cancer. J Surg Oncol 1999;72:24-31.
- 61.↵
Imoto S, Fukukita H, Murakami K, Ikeda H, Moriyama N. Pilot study on sentinel node biopsy in breast cancer. J Surg Oncol 2000;73:130-3.
- 62.↵
- 63.↵
Martin RC, Edwards MJ, Wong SL, Tuttle TM, Carlson DJ, Brown CM, et al. Practical guidelines for optimal gamma probe detection of sentinel lymph nodes in breast cancer: results of a multi-institutional study. For the University of Louisville Breast Cancer Study Group. Surgery 2000;128:139-44.
- 64.↵
- 65.↵
Cox CE, Bass SS, McCann CR, Ku NN, Berman C, Durand K, et al. Lymphatic mapping and sentinel node biopsy in patients with breast cancer. Annu Rev Med 2000;51:525-42.
- 66.↵
- 67.↵
- 68.↵
American Society of Breast Surgeons. Revised consensus statement on guidelines for performance of sentinel lymphadenectomy for breast cancer. 2000 Aug 25. Available: www.breastsurgeons.org/sentinel.htm (accessed 2001 June 25).
- 69.↵
Chaudhry R, Goel V, Sawka C. Breast cancer survival by teaching status of the initial treating hospital. CMAJ 2001;164(2):183-8. Available: www .cma .ca /cmaj /vol-164/issue-2/0183.htm
- 70.↵
Luft HS, Hunt SS, Maerki SC. The volume–outcome relationship: practice-makes-perfect or selective-referral patterns? Health Serv Res 1987;22:157-82.
- 71.↵
Grilli R, Minozzi S, TinazziA, Labianca R, Sheldon TA, Liberati A. Do specialists do it better? The impact of specialization on the process and outcomes of care for cancer patients. Ann Oncol 1998;9:365-74.
- 72.↵
Dowlatshahi K, Fan M, Bloom KJ, Spitz DJ, Pavel S, Snider HC Jr. Occult metastases in the sentinel lymph nodes of patients with early stage breast cancer. Cancer 1999;86:990-6.
- 73.↵
Braun S, Pantel K, Muller P, Janni W, Hepp F, Kentemichi CR, et al. Cytokeratin positive cells in the bone marrow and survival of patients with stage I, II or III breast cancer. N Engl J Med 2000;342:525-33.
- 74.↵
Borgen E, Beiske K, Trachsel S, Nesland JM, Kvalheim G, Herstad TK, et al. Immunocytochemical detection of isolated epithelial cells in bone marrow: non-specific staining and contribution by plasma cells directly reactive to alkaline phosphatase. J Pathol 1998;185:427-34.
- 75.↵
Lambrechts AC, Bosma AJ, Klaver SG, Top B, Perebolte L, van't Veer LJ, et al. Comparison of immunocytochemistry, reverse transcriptase polymerase chain reaction, and nucleic acid sequence-based amplification for the detection of circulating breast cancer cells. Breast Cancer Res Treat 1999;56:219-31.
- 76.↵
Hermanek P, Hutter RV, Sobin LH, Wittekind C. Classification of isolated tumor cells and micrometastasis. Cancer 1999;86:2668-73.
In this issue
Article tools
Respond to this article
Clinical practice guidelines for the care and treatment of breast cancer: 13. Sentinel lymph node biopsy
Jacques Cantin, Hugh Scarth, Mark Levine, Maria Hugi, The Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer
CMAJ Jul 2001, 165 (2) 166-173;
Related Articles
Cited By...
- Prediction of involvement of sentinel and nonsentinel lymph nodes in a Canadian population with breast cancer
- American Society of Clinical Oncology Guideline Recommendations for Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer
- Surgical management of early stage invasive breast cancer: a practice guideline
- Practice patterns of lymph-node mapping and sentinel-node biopsy for breast cancer in British Columbia
- Breast cancer guidelines
- Correction